Image Name

Enterprise News

Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Tablet Completes First Patient Dosing in Phase II Clinical Trial for Ankylosing Spondylitis

Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Tablet Completes First Patient Dosing in Phase II Clinical Trial for Ankylosing Spondylitis

The second-generation selective JAK1 inhibitor VC005 Tablet, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), recently initiated its Phase II clinical study for ankylosing spondylitis (AS). On April 26th, the first patient was successfully dosed at Peking University People's Hospital. VC005 Tablet demonstrated favorable metabolic properties, safety, and tolerability in the completed Phase I clinical study.

Time：2023-05-04 17:35

Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Gel Approved for Clinical Study in Mild-to-Moderate Atopic Dermatitis

Jiangsu Vcare's Second-Generation Selective JAK1 Inhibitor VC005 Gel Approved for Clinical Study in Mild-to-Moderate Atopic Dermatitis

Recently, the second-generation selective JAK1 inhibitor VC005 Gel, independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received approval from the NMPAto conduct clinical trials. The target indication is mild-to-moderate atopic dermatitis (AD). Related Phase I clinical trial work is scheduled to commence shortly.

Time：2023-03-21 17:39

Vcare 2022 Annual Review

Vcare 2022 Annual Review

I. Corporate Development and Infrastructure 　　① Wholly-owned subsidiary Nanjing Vcare successfully acquired Hubei Tianshu Pharmaceutical Co., Ltd. 　　② CDMO Business Technology Center completed and operational. 　　③ Established new technology platform laboratories. 　　④ Built a new Innovative Drug Synthesis Technology Center.

Time：2023-01-20 17:39

Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Series B to Accelerate Clinical Drug Development & CDMO Industrial Base

Jiangsu Vcare Closes Hundreds-of-Millions-of-RMB Series B to Accelerate Clinical Drug Development & CDMO Industrial Base

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed a Series B financing round exceeding CNY 200 million,which were led by Changjiang Venture Capital ,with participation from Hongcheng Capital and Hangzhou Huadian Investment, and continued support from Yangtze River Industry Group and SDIC Capital. The raised funds will be used to accelerate the clinical development of the company's core innovative drug products and the construction of its CDMO industrial base.

Time：2022-12-27 17:35

Jiangsu Vcare's Class 1 Novel Antiplatelet Drug Vicagrel Capsule Approved for Phase II Clinical Study in Ischemic Stroke

Jiangsu Vcare's Class 1 Novel Antiplatelet Drug Vicagrel Capsule Approved for Phase II Clinical Study in Ischemic Stroke

Recently, Vicagrel capsules, a Class 1 novel antiplatelet agent developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received Clinical Trial Approval from the NMPA for the target indication of minor ischemic stroke (MIS) or transient ischemic attack (TIA). The related Phase II clinical trial is set to begin shortly.

Time：2022-05-19 17:57

Jiangsu Vcare Closes Series A2 Financing

Jiangsu Vcare Closes Series A2 Financing

Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series A2 financing round. This marks the successful closing of the company’s Series A financing, bringing the total Series A funding to nearly $60 million. This round was led by existing investor SDIC Capital, with co-investment from Yangtze River Industry Group. The proceeds will primarily support the R&D of innovative drug candidates as well as the construction of R&D and production bases for its CDMO business.

Time：2022-05-06 17:26

First Dosing of Participant in the First Clinical Trial of Jiangsu Vcare's Highly Selective JAK1 Inhibitor VC005 Tablets

First Dosing of Participant in the First Clinical Trial of Jiangsu Vcare's Highly Selective JAK1 Inhibitor VC005 Tablets

On November 19, 2021, the first clinical trial participant was dosed with VC005 tablets, a highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The dosing was completed at the Phase I Clinical Research Center of the First Hospital of Jilin University, and the participant has now successfully completed the safety observation period.

Time：2021-11-22 17:43

Initiation Meeting of FDA-FE Clinical Study of Vicagrel Capsules

Initiation Meeting of FDA-FE Clinical Study of Vicagrel Capsules

On August 18, the kick-off meeting of the FDA-FE clinical study of Vicagrel Capsules, a Class I new drug of Jiangsu Vcare Pharmatech Co., Ltd. (Jaingsu Vcare), was held at the Phase I Clinical Research Center of the First Hospital of Jilin University. This marks the official launch of the FDA clinical study of Vicagrel in the United States and the supporting Phase III clinical study in China.

Time：2021-08-18 08:19

< 1...789...11 >
Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Company Address:

No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China

Subsidiary NJVcare Website：

en.njvcare.com

Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Scan to see

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.

SEO

图片名称

苏公网安备32011202001742号

Powerby：www.300.cn nanjing.300.cn